Mali Barbi, Medical Oncologist at Northwell Health, shared a post on X:
“ASCO26 | The RUBY trial just answered the question we never thought we’d ask in advanced endometrial cancer: can we cure these patients?
dMMR rectal cancer proved immunotherapy could eliminate a tumor entirely. RUBY asked the same question – and the answer is yes.
Dostarlimab + chemotherapy in dMMR endometrial cancer. 55.6 months median follow-up. Only 4 new PFS events in 2.5 years. 4-year PFS: 57.9% vs 15.7%.
But the headline isn’t the survival curve. It’s the method.
A formal mixture cure model, separating patients into those who will recur and those who never will, estimates 54% of patients are cured. Not disease control. Not durable response. Cured.
That word has never belonged in advanced endometrial cancer before. Covering the oral presentation live from Chicago.
More from ASCO26 all week. Follow along. Gynecologic Oncology, endometrialCancer.”
Other articles about ASCO26 on OncoDaily.